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Abstract: COPD is characterized by a pulmonary and systemic inflammatory process. Several 
authors have reported the elevation of multiple inflammatory markers in patients with COPD; 
however, their use in routine clinical practice has limitations. The neutrophil-to-lymphocyte ratio 
(NLR) is a useful and cost-effective inflammatory marker derived from routine complete blood 
count. We performed a systematic literature review using the PRISMA statement. Twenty-two 
articles were included, recruiting 7,601 COPD patients and 784 healthy controls. Compared 
with controls, COPD patients had significantly higher NLR values. We found a significant cor-
relation between the NLR and clinical/functional parameters (FEV
1
, mMRC, and BODE index) 
in COPD patients. Elevation of the NLR is associated with the diagnosis of acute exacerbation 
of COPD (pooled data propose a cut-off value of 3.34 with a median sensitivity, specificity, 
and area under the curve of 80%, 86%, and 0.86, respectively). Additionally, increased NLR 
is also associated with the diagnosis of a bacterial infection in exacerbated patients, with a 
cut-off value of 7.30, although with a low sensitivity and specificity. The NLR is an independent 
predictor of in-hospital and late mortality after exacerbation. In conclusion, the NLR could be 
a useful marker in COPD patients; however, further studies are needed to better identify the 
clinical value of the NLR.
Keywords: acute exacerbations of COPD, bacterial infection, mortality in COPD, inflammatory 
biomarkers, eosino philia, GOLD stage
Introduction
COPD is a major public health problem worldwide and is characterized by poorly 
reversible airflow limitation and/or alveolar abnormalities. It is usually associated by 
persistent respiratory symptoms, disease progression, and, in some patients, multiple 
acute exacerbations.1 COPD accounted for 6% of all deaths globally in 2012 and is 
currently ranked as the fourth leading cause of death worldwide with a projection to 
increase in the coming decade.2,3 Chronic inflammation of the airways and the lung 
parenchyma is the classic paradigm for the pathogenesis of COPD and is associated 
with goblet cell proliferation, gland hyperplasia, fibrosis, collapse of small airways, 
and parenchymal destruction.4 However, there is increasing evidence that COPD also 
results in systemic inflammation and extra-pulmonary manifestations.5
Acute exacerbation of COPD (AECOPD) is related to more severe airway and 
systemic inflammation than in stable disease patients, and is associated with worse 
clinical symptoms, reduced lung function, increase hospitalization and intensive care 
unit admission rates, and more intensive treatments.6,7 The main causes of exacerba-
tions in COPD are viral or bacterial infections, while 15%–20% are caused by other 
microorganisms or unspecified causes.8
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There are limited data regarding inflammatory biomarkers 
in stable and exacerbated patients in standard clinical practice. 
However, recent studies have shown that the neutrophil-to-
lymphocyte ratio (NLR) is a reliable marker of systemic 
inflammation and a routinely performed test (complete blood 
counts), because of its rapidity and easy detection, avail-
ability, and cost-effectiveness.9,10 Based on the physiologi-
cal response of circulating leukocytes to precipitating stress 
factors, with increased numbers of neutrophils and fewer 
lymphocytes, the ratio between these two subgroups has been 
evaluated in periods of inflammation in different diseases, 
such as lung cancer, colorectal cancer, end-stage renal 
disease, and acute coronary syndrome, among others.11–14
The aim of the present systematic review was to investi-
gate 1) the role of the NLR in the severity of COPD accord-
ing to clinical and functional outcomes (airflow obstruction 
[FEV
1
], dyspnea [mMRC], and exercise capacity [BODE 
index]); 2) the relation between NLR and other inflamma-
tory biomarkers; and 3) the ability of the NLR to detect or 




This systematic review was performed in accordance with 
the PRISMA statement.15
Search strategy
The search was carried out using the databases PubMed/
Medline, Google Scholar, Scielo, and Scopus, using a 
combination of the key words: “neutrophil-to-lymphocyte 
ratio”, “NLR”, “chronic obstructive pulmonary disease”, 
“COPD”, “lung disease”, “exacerbation”, “prognosis”, and 
“lung function”. The search included articles published up to 
January 2018 and was limited to English language studies. 
The automatic search was complemented by a manual 
search to identify relevant articles. The search results were 
exported to the reference manager EndNote (Thompson 
Reuters), with a total of 482 records identified after duplicates 
were removed.
Inclusion criteria and study eligibility
The articles were screened by abstracts and full text. Dis-
agreements were resolved by a senior author. Articles that 
contained the following information were included: 1) diag-
nosis of COPD according to the GOLD or the American 
Thoracic Society or the European Respiratory Society, or 
clearly defined similar criteria; 2) analysis of the associations 
between NLR and clinical features or outcomes of COPD 
patients; and 3) NLR cut-off value. The exclusion criteria 
were 1) review articles, editorial comments, letters, confer-
ence abstracts; 2) preclinical studies; or 3) full text unavail-
able and non-English article.
Data extraction
A standardized extraction form was used to collect data. The 
data extracted were: 1) authors, year of publication, study 
design, and sample size; 2) participant characteristics (age, 
gender); 3) NLR cut-off value and accuracy characteristics; 
4) total NLR value in patient subgroups (healthy controls, 
stable COPD, exacerbated COPD); 5) total NLR value in dif-
ferent severity subgroups according to GOLD; 6) correlation 
coefficient between NLR and FEV
1
; 7) correlation coefficient 
between NLR and clinical parameters of COPD (6-minute 
walking distance, body mass index, airflow obstruction, 
and mMRC dyspnea scale); and 8) correlation coefficient 
between NLR and other inflammatory markers (C-reactive 
protein [CRP], erythrocyte sedimentation rate [ESR], and 
white blood cells).
Quality assessment
The quality of the included studies was analyzed using the 
Newcastle-Ottawa Quality Assessment Scale (NOS) for 
cohort, case-control, and cross-sectional studies. This scale 
is based on three characteristics: selection, comparability, and 
outcome or exposure (in case-control studies).16 In this “star 
system”, a maximum of nine stars can be given for cohort 
and case-control studies, while cross-sectional studies can be 
given a maximum of ten stars. The thresholds for converting 
the NOS to Agency for Healthcare Research and Quality 
standards (good, fair, and poor) were: good quality – 3 or 
4 stars in selection domain, 1 or 2 stars in comparability 
domain, and 2 or 3 stars in outcome/exposure domain; fair 
quality – 2 stars in selection domain, 1 or 2 stars in com-
parability domain, and 2 or 3 stars in outcome/exposure 
domain; and poor quality – 0 or 1 star in selection domain, or 
0 stars in comparability domain, or 0 or 1 stars in outcome/
exposure domain.17
Statistical analysis
The continuous variables were expressed as mean ± SD. 
In articles in which the continuous variables were expressed 
as median and interquartile range, mean and SD were 
calculated according to Hozo et al.18 Accuracy data and the 
correlation between the NLR and clinical parameters or 
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Role of neutrophil-to-lymphocyte ratio in COPD
correlation coefficient or Spearman’s Rho. The differences 
in NLR between groups were estimated using one-way 
ANOVA with Bonferroni as post hoc test or an unpaired 
t-test. Statistical analysis was performed using SPSS v22 
(IBM SPSS Inc., Armonk, NY, USA). Statistical significance 
was considered with a value of P,0.05.
Results
Selected studies
Figure 1 shows the flow diagram of the studies. A total of 
803 references were found through the literature search 
(795 automatic searches and eight manual searches). Initially, 
321 were duplicates, and the remaining 483 were screened by 
title and abstract; of these, 459 were excluded and 25 were 
selected for full-text screening, of which 22 were eligible 
for inclusion, recruiting a total of 8,385 patients (7,601 
COPD patients and 784 healthy controls) with a mean age 
of 65.65±6.20 years, 5,812 (70%) males, and 2,573 (30%) 
females. Table 1 summarizes the characteristics of the articles 
and the population included. Articles in which the same 
group of COPD patients was evaluated in both periods of the 
disease (stable and exacerbated) were considered as provid-
ing independent data for statistical analysis.10,19–21
Quality assessment
The present systematic review included five cohort studies, 
six cross-sectional studies, and eleven case-control studies. 
Using the NOS form, 20 articles were identified as high 
quality (five cohort studies, five cross sectional studies, and 
ten case-control studies), and only two articles were identi-
fied as poor quality (one cross-sectional study and one case-
control study) (Table 2).
Neutrophil-to-lymphocyte ratio and 
COPD exacerbation
The mean NLR values of healthy controls and stable and 
exacerbated COPD patients were extracted from 8,10,21,23–28 
18,9,10,19–21,23–25 and 17 articles,9,10,19–26,28,32,34–38 respectively. 
The pooled data showed that the mean NLR values of healthy 
controls, and stable and exacerbated COPD patients were 
1.71±0.22, 2.97±1.10, and 7.76±3.79, respectively (Table 3). 
The NLR in COPD patients with exacerbation was significantly 
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higher than that in stable patients and healthy controls 
(P,0.0005) (Figure 2). There were no significant differences 
between stable COPD patients and healthy controls when 
one-way ANOVA with Bonferroni post hoc test was used, but 
differences were found using an unpaired t-test (P,0.0001).
Two observational prospective studies have assessed the 
NLR as an independent predictor of COPD exacerbation 
during the first year follow-up, although only one found statisti-
cally significant differences (OR 2.083, 95% CI: 0.918–4.723, 
P=0.07925 and OR 2.05, 95% CI: 1.03–4.06, P=0.04133).
The accuracy of NLR data for detecting COPD exacer-
bation was described in seven articles (Table 4).9,10,23,24,26,34,35 
The median cut-off value for a high NLR was 3.34 (range 
1.5–3.35) with a sensitivity, specificity, and under the 
curve (AUC) being in the range 69%–93%, 59%–90%, and 
0.58–0.89, respectively. Three articles described the accuracy 
of NLR data for distinguishing between bacterial and non-
bacterial exacerbation in patients admitted to the emergency 
room with a diagnosis of acute exacerbation of COPD.28,32,36 
The median cut-off value for detecting bacterial infection 
in exacerbated patients was 7.30 (range 4.52–11.5) with a 
sensitivity, specificity, and AUC in the range 61%–91%, 
46%–73.1%, and 0.58–0.79, respectively (Table 4).
Correlation between NLR and clinical 
outcomes in COPD patients
Six authors evaluated the correlation between NLR and 
FEV
1
.24–26,30,33,34 In four articles, the data were analyzed using 
Pearson’s correlation coefficient24–26,33 and in two using Spear-
man’s rank correlation (Spearman’s Rho) (Table 5). Five 
articles showed a significant negative correlation between 
the two parameters. Pooled data showed a median Pearson’s 
correlation of −0.22 (range −0.17 to −0.28) and a median 
Spearman’s correlation of −0.43 (range −0.38 to −0.49).
Three articles evaluated the relationship between the NLR 
values and GOLD stages,22,23,31 and a pooled analysis showed 
no significant differences in NLR values between GOLD 
stages (GOLD 1/2: 2.40±0.36 and GOLD 3/4: 2.22±0.36; 
P=0.63). However, one study showed positive linear relation-
ship between NLR and COPD severity in the stable group, 
whereas the results in patients exacerbated in stages 1 and 4 
were similar (Table 6).23
The correlation between NLR and other clinical param-
eters was evaluated by two authors.25,30 However, the 
heterogeneity in the statistical analysis precludes pooling 
the results. Furutate et al30 showed a significant positive 
correlation between NLR and mMRC or BODE index 
Table 1 Characteristics of included articles and population




Gender Number of patients
Male Female Control COPD Total  
patientsStable Exacerbated Total  
COPD
Günay et al, 201422 Retrospective 65.76 (7.62) 216 103 50 178 91 269 319
Tanrıverdi et al, 201536 Prospective 71.70 (9.50) 56 21 – – 77 77 77
Sørensen et al, 201529 Prospective 70.13 (3.16) 191 195 – 386 – 386 386
Taylan et al, 201510 Retrospective 63.97 (11.60) 117 63 80 100 100 100 180
Saltürk et al, 201519 Retrospective 67.75 (6.05) 523 124 – 647 647 647 647
Duman et al, 201520 Retrospective 70.50 (4.90) 1,116 588 – 1,704 1,704 1,704 1,704
Kurtipek et al, 20159 Prospective 64.66 (9.79) 94 0 – 48 46 94 94
Bilir et al, 201623 Retrospective 54.90 (13.97) 519 98 215 216 186 402 617
Furutate et al, 201630 Prospective 71.20 (7.46) 137 4 – 141 49 141 141
In et al, 201624 Retrospective 65.67 (9.17) 112 31 40 56 47 103 143
Duyar, 201631 Retrospective 67 (NS) 39 0 – 39 – 39 39
van de Geijn et al, 201632 Retrospective 67.55 (2.45) 22 18 – 17 23 40 40
Lee et al, 201633 Prospective 70.85 (7.70) 809 76 – 885 233 885 885
Lee et al, 201625 Prospective 70.4 (6.13) 139 9 28 61 59 120 148
Yousef and Alkhiary, 201726 Prospective 48.9 (8.29) 188 0 60 60 68 128 188
Xiong et al, 201727 Prospective 69.65 (7.15) 252 412 296 368 – 368 664
Rahimirad et al, 201737 Retrospective 69.89 (10.87) 174 141 – – 315 315 315
Kumar et al, 201721 Retrospective 71 (10) 93 88 – 181 181 181 181
Mohamed-Hussein et al, 201734 Retrospective 58.1 (16.95) 107 41 – 74 74 148 148
Yao et al, 201738 Retrospective 61 (10) 200 103 – – 303 303 303
Farah et al, 201728 Prospective 58.1 (10.70) 72 28 15 13 72 85 100
Acartürk et al, 201735 Retrospective 66 (13) 636 430 – 993 73 1,066 1,066
Note: Values are given as geometric mean ± SD.
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Role of neutrophil-to-lymphocyte ratio in COPD
Table 2 Study quality assessment using the Newcastle-Ottawa scale
Studies Selection Comparability Outcome Total stars
Cohort studies
Sørensen et al, 201529    9
Saltürk et al, 201519    8
Duman et al, 201520    9
Lee et al, 201633    8
Kumar et al, 201721    8
Studies Selection Comparability Exposure Total stars
Cross-sectional studies
Tanrıverdi et al, 201536    7
Kurtipek et al, 20159    9
Bilir et al, 201623    10
Furutate et al, 201630    9
Duyar, 201631  –  5
Acartürk et al, 201735    8
Studies Selection Comparability Exposure Total stars
Case-control studies
Günay et al, 201422    8
Taylan et al, 201510    8
In et al, 201624    8
van de Geijn et al, 201632    7
Lee et al, 201625    9
Yousef and Alkhiary, 201726    9
Xiong et al, 201727    9
Rahimirad et al, 201737    8
Mohamed-Hussein et al, 201734  –  6
Yao et al, 201738    7
Farah et al, 201728    7
Table 3 NLR value of healthy controls, and stable and exacerbated COPD patients
Author, year NLR, mean (SD)
Control Stable COPD Exacerbated COPD P-value
Günay et al, 201422 1.71 (0.41) 2.59 (1.05) 4.28 (2.38) ,0.001
Tanrıverdi et al, 201536 – – 18.5 (16.60) –
Sørensen et al, 201529 – 3.08 (0.76) – –
Taylan et al, 201510 1.7 (0.90) 3.1 (2.50) 7.1 (5.40) ,0.001
Saltürk et al, 201519 – 5.86 (1.80) 9.45 (2.80) –
Duman et al, 201520 – 5.18 (1.39) 6.12 (1.73) –
Kurtipek et al, 20159 – 2.75 (1.11) 7.99 (5.72) 0.001
Bilir et al, 201623 1.9 (0.66) 2.41 (2.90) 4.22 (2.51) ,0.001
Furutate et al, 201630 – 2.56 (0.23) – ,0.001
In et al, 201624 1.68 (0.41) 2.67 (1.13) 5.78 (3.14) ,0.05
Duyar, 201631 – 2.14 (0.40) – –
van de Geijn et al, 201632 – 3.08 (1.51) 5.89 (4.92) ,0.001
Lee et al, 201633 – 2.4 (0.27) – –
Lee et al, 201625 1.4 (0.50) 2.4 (0.70) 12.4 (10.60) ,0.001
Yousef and Alkhiary, 201726 1.45 (0.21) 2.36 (0.55) 4.44 (1.61) ,0.001
Xiong et al, 201727 2.02 (1.92) 2.98 (1.89) – –
Rahimirad et al, 201737 – – 10.22 (11.19) –
Kumar et al, 201721 – – 10 (9) –
Mohamed-Hussein et al, 201734 – 1.2 (0.70) 3.7 (0.30) ,0.05
Yao et al, 201738 – – 7.92 (8.79) –
Farah et al, 201728 1.9 (0.60) 3.8 (2.20) 6.3 (5.40) ,0.001
Note: Values are given as geometric mean ± SD.
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(Rho=0.403; P,0.001 and Rho=0.46; P,0.001, respec-
tively). Likewise, Lee et al25 showed a significant positive 
correlation between these parameters (r=0.39; P=0.01 and 
r=0.45; P=0.003, respectively).
NLR and other inflammatory biomarkers 
in COPD patients
Data on the correlation between NLR and other inflam-
matory parameters were extracted from ten articles 
(Table 7).9,10,22–24,26,28,30,34,38 CRP was the most frequently 
evaluated parameter.9,10,22–24,26,28,30,38 The pooled data show 
that the median correlation between NLR and CRP values 
was Rho=0.43 (range 0.20–0.48) in stable COPD patients. 
In exacerbated COPD patients, four articles analyzed the 
data using Pearson’s correlation coefficient9,10,26,38 and two 
using Spearman’s rank correlation (Spearman’s Rho),22,23 
showing a median of 0.46 (range 0.28–0.60) and 0.59 (range 
0.53–0.66), respectively. In all articles, the correlation was 
statistically significant. Analyzing the comparative individual 
studies, a similar trend was observed in both CRP and NLR 
markers during the stable and exacerbation phases of COPD 
(CRP 7.39±8.15 mg/dL stable vs 26.49±24.32 mg/dL exac-
erbated; P,0.001). The median cut-off value of CRP for 
detecting AECOPD was 2.56 mg/dL (range 1.17–3.35) with 
a sensitivity, specificity, and AUC in the range 68%–91%, 
52%–62%, and 0.75–0.82, respectively.
Figure 2 Neutrophil-to-lymphocyte ratio in healthy controls, and stable and exacerbated COPD patients. 
Note: Box plots represent median, interquartile range, and range with outliers plotted separately.
Table 4 Accuracy data of NLR for detecting COPD global and bacterial infection exacerbation
Author, year Cut-off Sensitivity (%) Specificity (%) AUC (95% CI)
Kurtipek et al, 20159,a 3.30 87 82 0.88 (NS)
Tanrıverdi et al, 201536,b 11.50 61 52 0.58 (0.45–0.71)
Taylan et al, 201510,a 3.29 80.80 77.70 0.89 (0.84–0.94)
Bilir et al, 201623,a 3.35 69 59 0.68 (0.63–0.73)
In et al, 201624,a 3.34 78.70 73.20 0.86 (0.79–0.93)
van de Geijn et al, 201632,b 4.52 91 46 0.75 (0.60–0.91)
Yousef and Alkhiary, 201726,a 3.12 86.70 76.70 0.88 (0.90–1.00)
Mohamed-Hussein et al, 201734,a 1.50 93 90 0.68 (0.54–0.81)
Farah et al, 201728,b 7.30 76.80 73.10 0.79 (NS)
Acartürk et al, 201735,a 3.54 78 69 –
Notes: aNLR for detecting COPD global exacerbation; bNLR for detecting COPD bacterial infection exacerbation.
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Role of neutrophil-to-lymphocyte ratio in COPD
The second most studied parameter was ESR. The 
pooled data show that the median correlation between 
NLR and ESR values was r=0.42 (range 0.27–0.71)10,26 and 
Rho=0.49 (range 0.29–0.55)34 in exacerbated patients, and 
only one article showed a significant correlation between 
parameters in total COPD patients (Rho=0.26; P,0.001).24 
Likewise, three articles showed a significant positive cor-
relation between NLR and leukocytes.10,26,34 The pooled 
data show a median Pearson’s correlation of r=0.49 (range 
0.30–0.69). Only one article reported Spearman’s Rho 
(Rho=0.33; P,0.05),34 and the correlation between NLR 
and leukocytes was evaluated only in exacerbated COPD 
patients.
Analyzing individual studies for which data were 
available,9,10,19,20,22–24,26,28,32 although all markers showed sig-
nificant differences in mean values between the stable and 
exacerbation phases, the difference was quantitatively greater 
in the NLR (3.57±1.54 stable vs 6.72±4.77 exacerbated) than 
in the absolute values of neutrophils (5.76±1.08×103/µL 
stable vs 7.36±1.55×103/µL exacerbated) or lymphocytes 
(1.54±0.59×103/µL stable vs 1.19±0.54×103/µL exacer-
bated) assessed separately, with differences between their 
absolute values being 3.15, 1.6, and −0.35, respectively.
Two studies19,20 analyzed the relationship between eosino-
philia and the NLR in acute and stable phase patients. In both 
studies, the NLR was higher in patients with a lower percent-
age of eosinophils (,2%) both in stable COPD (overall mean 
value, 6.99±1.25 vs 3.99±0.71, P=0.001) and in AECOPD 
(11.33±2.11 vs 4.25±0.65, P=0.001).
Prognostic significance of NLR in COPD 
patients
Five articles found that the NLR represents an independent 
predictor of mortality in COPD patients (Table 8).19–21,27,37 
Saltürk et al19 and Rahimirad et al37 conducted a multivariate 
analysis and found that high NLR values represent an inde-
pendent predictor of in-hospital mortality during exacerba-
tion, showing 2–3.5-fold more probability (OR 1.96, 95% 
CI: 1.13–3.39; P=0.016 and OR 3.586, 95% CI: 1.69–7.60; 
P=0.001, respectively) with a median NLR cut-off value of 
10 (range 4–16). On the other hand, Duman et al,20 Xiong 
et al,27 and Kumar et al21 found that the NLR is an indepen-
dent predictor of early (first 90 days) and late (within 6 and 
24 months) mortality during the follow-up after exacerbation. 
According to Duman et al,20 there was an almost twofold 
(OR 1.79, 95% CI: 1.37–2.34; P=0.001) higher probability 
of mortality within 6 months after exacerbation with an NLR 
cut-off value of 7, while Xiong et al27 showed that there was 
an almost fourfold (OR 3.95, 95% CI: 2.54–6.38; P,0.001) 
higher probability of mortality within 24 months after exac-
erbation with an NLR cut-off value of 3.3.
Discussion
COPD is characterized by an increase in pulmonary and 
systemic inflammatory responses39 that are maintained after 
smoking cessation and could progressively increase over 
time.40 Different studies have shown that lung inflammation 
induced by COPD is mediated by innate and adaptive immune 
system deprivation.41,42
Changes in the innate immune system in COPD patients 
are related to injury of the alveolar epithelium, a decrease 
in phagocytosis mediated by macrophages, a reduction in 
dendritic cells in airways, and an increase in neutrophil 
migration into the airways that is not accompanied by cor-
rect bacterial clearance. This neutrophil migration stimulates 
cytokine production and subsequent destruction of lung 
tissue,40,43–45 which leads to changes in the microbiome of 
patients with COPD that seem to be related to the perpetua-
tion of the inflammatory response in the airway despite the 
cessation of smoking.46
Table 5 Correlation data between NLR and FEV1
Author, year Correlation  
coefficient
P-value
Furutate et al, 201630 Rho=−0.387 ,0.001
In et al, 201624 r=−0.288 0.003
Lee et al, 201633 r=−0.176 ,0.001
Lee et al, 201625 r=−0.285 0.071
Yousef and Alkhiary, 201726 r=−0.176 ,0.001
Mohamed-Hussein et al, 201734 Rho=−0.498 ,0.01
Abbreviations: r, Pearson’s correlation coefficient; Rho, Spearman’s rank 
correlation coefficient; NLR, neutrophil-to-lymphocyte ratio.
Table 6 NLR during stable and exacerbation periods according to GOLD stage
Author, year Group GOLD 1 GOLD 2 GOLD 3 GOLD 4 P-value
Günay et al, 201422 Stable 2.44 (1.19) 2.90 (2.00) 2.46 (1.41) 3.16 (4.87) 0.254
exacerbation 2.29 (4.39) 4.28 (3.51) 4.35 (4.26) 6.15 (5.38) 0.178
Bilir et al, 201623 Stable 1.64 (1.60) 2.33 (2.09) 2.60 (3.58) 2.66 (3.86) ,0.001
exacerbation 6.19 (2.94) 4.18 (4.48) 3.47 (3.53) 6.29 (6.38) 0.028
Duyar, 201631 Stable 1.81 (0.33) 2.57 (0.34) 0.091
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Changes in the adaptive immune system are due to an 
increase in CD8+ T lymphocytes within the airway,42 which 
has been related to the production of larger amounts of 
cytotoxic perforins, granzyme B, and macrophage elastase 
(MMP-12), leading to tissue damage.47 On the other hand, 
some studies have found that CD4+ T lymphocytes partici-
pate in the amplification of the adaptive immune response.48 
In addition, they seem to play a role in the development of 
autoimmunity;49 however, the clinical role of these data 
remains to be elucidated.
Several studies have suggested that patients with COPD 
present elevated serum inflammatory markers. It has been 
estimated that ~70% of patients with COPD have at least 
one elevated serum inflammatory parameter.49 Some data 
have shown that the persistent elevation of inflammatory 
markers is related to the progression of the disease,50 clinical 
and functional parameters,51 and the development of comor-
bidities.40 The most studied serum inflammatory markers 
are CRP, IL-6, and TNF-α.50 However, their use in routine 
clinical practice has limitations, while NLR is a rapid, easy, 
and cost-effective method derived from routine complete 
blood count tests. The NLR has been reported to be a useful 
indicator of clinical outcome and severity in malignant and 
inflammatory diseases.51–54
In the present study, the NLR showed a positive and 
significant correlation with other traditional inflammatory 
markers such as CRP, leukocytes, and ESR. Analyzing 
the comparative individual studies, a similar trend was 
observed in both CRP and NLR markers during the stable 
and exacerbation phases of COPD. Therefore, the data seem 
to indicate that both are equally effective in the detection 
of AECOPD. However, NLR is easy to calculate from a 
routine complete blood count and is cheaper than serum 
CRP-level measurement. On the other hand, the difference 
is quantitatively greater in the NLR compared to absolute 
values of neutrophils and lymphocytes, which is expected, 
since the NLR includes both biomarkers. This analysis 
shows the potential usefulness of NLR as an inflammatory 
marker in patients with COPD and indicates the possibility 
of using the NLR as a useful marker in routine clinical 
Table 7 Correlation between NLR and other inflammatory parameters in COPD patients
Correlation Author/year COPD
Stable Exacerbated Total
NLR/CRP Günay et al, 201422 Rho=0.485, P,0.001 Rho=0.665, P,0.001 –
Taylan et al, 201510 – r=0.415, P,0.001 –
Kurtipek et al, 20159 – r=0.512, P,0.001 –
Bilir et al, 201623 Rho=0.436, P,0.001 Rho=0.534, P,0.001 –
Furutate et al, 201630 Rho=0.209, P=0.015 – –
In et al, 201624 – – r=0.641, P,0.001
Yousef and Alkhiary, 201726 – r=0.609, P,0.000 –
Yao et al, 201738 – r=0.281, P,0.001 –
Farah et al, 201728 – – r=0.556, P,0.000
NLR/ESR Taylan et al, 201510 – r=0.275, P=0.035 –
In et al, 201624 – – r=0.276, P=0.005
Yousef and Alkhiary, 201726 – r=0.714, P,0.000 –
Mohamed-Hussein et al, 201734 – Rho=0.558, P,0.01 –
NLR/WBC Taylan et al, 201510 – r=0.304, P=0.002 –
Yousef and Alkhiary, 201726 – r=0.694, P,0.000 –
Mohamed-Hussein et al, 201734 – Rho=0.330, P,0.01 –
Abbreviations: CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; NLR, neutrophil-to-lymphocyte ratio; Rho, Spearman’s rank correlation coefficient; r, 
Pearson’s correlation coefficient; WBC, white blood cell.
Table 8 Predictive value of NLR in COPD patients’ mortality based on multivariate analysis
Author, year Cut-off Odds ratio 95% CI P-value Event
Saltürk et al, 201519 NLR $16 1.96 1.13–3.39 0.016 In-hospital mortality (respiratory failure)
Duman et al, 201520 NLR $7 1.79 1.37–2.34 0.001 Late mortality (within 6 months)
Xiong et al, 201727 NLR $3.3 3.95 2.54–6.38 ,0.001 Late mortality (within 24 months)
Rahimirad et al, 201737 NLR $4 3.586 1.69–7.60 0.001 In-hospital mortality
Kumar et al, 201721 – 0.95 0.84–1.08 0.46 Early mortality (at 90 days after hospital admission)
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practice, although more validation studies are required in 
this regard.
The pooling of data in this systematic review demon-
strated that the NLR value was significantly elevated in 
stable COPD patients compared with healthy subjects, which 
suggests that systemic inflammation is persistent in this popu-
lation. This observation is consistent with other published 
data that showed elevation of inflammatory markers such as 
IL-6 and CRP in patients with stable COPD compared with 
healthy controls.55–57
It was also shown that exacerbated COPD patients had 
significantly higher NLR values compared with stable COPD 
patients. In addition, it was observed that the NLR decreased 
in patients with exacerbated COPD after recovery of the 
exacerbation.10,19,21 These findings are consistent with other 
studies in which the same behavior of other inflammatory 
markers was observed, along with a greater inflammatory 
response during exacerbation of COPD.58,59 Taken together, 
these data suggest that the NLR is a marker that could be 
used to evaluate the inflammatory status of patients with 
COPD and predict the remission of the inflammatory process 
during exacerbations.
In the present systematic review, only one out of two 
single studies found that elevation of the NLR is an indepen-
dent predictor of acute exacerbation in patients with COPD, 
with a twofold increase in the likelihood of exacerbation in 
patients with a high NLR in the stable phase. A previous 
prospective study demonstrated that the single best predictor 
of future exacerbations, across all GOLD stages, was a treated 
exacerbation in the year before study entry (OR 4.30, 95% CI: 
3.58–5.17; P,0.001).60 Other studies have also shown a 
predictive value of other inflammatory markers for acute 
exacerbation in COPD patients.58,61 Hence, the discordant 
findings of the NLR in the present review do not support the 
value of this marker as a predictor of future exacerbations. 
However, the NLR seems to be a good marker for detecting 
an acute exacerbation in COPD patients. The pooled data 
indicate that a cut-off value of 3.34 would allow the diagnosis 
of acute exacerbation with a median AUC of 0.86, sensitivity 
of 80%, and specificity of 86%. Similarly, the pooled data 
suggest a median cut-off value of 7.30 for detecting infec-
tious exacerbation of COPD patients with a median AUC of 
0.75, but with a wide range of cut-off values and rather low 
sensitivity (76.8%) and specificity (52%). The possibility that 
the NLR could predict bacterial exacerbation appears more 
interesting, in view of its clinical implications. Although 
the results shown here do not support this hypothesis, future 
studies are required to validate this information.
In our review, the NLR was higher in patients with a lower 
percentage of eosinophils (,2%) both in stable COPD and in 
AECOPD, and it should be noted that these patients presented 
greater therapeutic failure after corticosteroid treatment for 
the exacerbation. These findings agree with other studies 
that show a negative correlation between the eosinophil 
count and bacterial isolates in the sputum of patients with 
stable COPD.62 The percentage of blood eosinophils is also 
inversely correlated to the presence of bacterial infection in 
AECOPD.62 Hence, the combination of both markers (NLR 
and eosinophilia) could identify a therapeutic phenotype 
(the one that requires antibiotic and/or the one that requires 
systemic corticosteroids). Therefore, NRL could be used to 
monitor the exacerbation and to support therapeutic deci-
sion making.
On the other hand, no statistically significant differences 
were found in the NLR when patients were stratified using 
the GOLD airflow obstruction classification. However, one 
study showed a positive linear relationship between NLR 
and COPD severity in the stable group.23 The data regarding 
the association of inflammatory markers with GOLD clas-
sification are contradictory. In this regard, De Moraes et al55 
found no direct association between IL-6 and IL-8 and the 
severity of COPD in ex-smokers. Nevertheless, Mathanraj 
et al63 and Torres-Ramos et al56 reported a significant increase 
in TNF-α and CRP, respectively, according to GOLD stage. 
The findings in the different studies show the heterogeneity of 
the cohorts studied and the potential impact of comorbidities 
associated with COPD on systemic inflammatory markers. 
In addition, a high percentage of patients in GOLD stage II 
(about 22% according to the ECLIPSE study)60 also have 
frequent exacerbations, which are related to an increased and 
persistent inflammatory status in the stable stage.
The relationship between inflammatory markers and 
clinical/functional parameters in COPD patients was 
described in some articles. A positive correlation between 
IL-6 and a rapid decline in FEV
1
 has been demonstrated 
previously.51,59 Other authors reported a significant correla-
tion between IL-6, CRP, and BODE index.64,65 These data 
suggest that the inflammatory status of COPD patients is 
associated with disease progression, and worsening dysp-
nea and exercise tolerance.55 In the present review, some 
authors found a moderate correlation between NLR and 
FEV
1
, mMRC, and BODE index. These findings suggest 
that NLR could be used as a clinical performance marker in 
COPD patients.25,30
The prognostic value of different inflammatory markers in 
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In a cross-sectional prospective study, Shafiek et al66 found 
that high levels of IL-6 predict in-hospital mortality. Simi-
larly, a recent meta-analysis found that a high baseline level 
of CRP is significantly associated with higher late mortality in 
COPD patients.67 Other inflammatory markers such as IL-1β 
and fibronectin have also been described to be associated with 
mortality of COPD.68 In the present study, we found that the 
NLR is an independent predictor of in-hospital mortality, with 
2–3.5-fold higher probability of mortality with a median NLR 
cut-off value of 10. In addition, the NLR seems to be an inde-
pendent predictor of late mortality, with a high NLR value 
being associated with two- to four fold higher probability of 
death after exacerbation. All-cause mortality analysis is the 
method most usually performed in the studies, and the influ-
ence of other systemic diseases (such as lung cancer) on the 
NLR may introduce a certain bias. However, in favor of the 
NLR as an AECOPD biomarker, Rahimirad et al37 showed a 
statistically significant relationship between the ratio and the 
in-hospital mortality due to respiratory causes.
Regarding the potential effect of the patient’s treatment 
on the NLR, most studies in this review excluded patients 
with a history of antibiotic treatment and the use of systemic 
steroids in at least the two preceding months. Hence, treat-
ment with steroids was started at the time of AECOPD diag-
nosis; it was thus able to influence the subsequent neutrophil 
and lymphocyte counts, but not the baseline measurement. 
Dividing patients into two groups according to systemic 
glucocorticoid use at baseline, Sørensen et al29 concluded 
that treatment with systemic glucocorticoids has a significant 
impact on the ability of inflammatory biomarkers to predict 
all-cause mortality, with higher mortality in the group not 
undergoing this treatment. The use of inhaled corticosteroids 
to treat COPD patients is not recorded in the studies, and so 
the potential effect of this therapy on the NLR is unknown.
Limitations
There are several limitations in this systematic review. First, 
most studies included were retrospective, with the possibility 
of selection bias. Second, most studies included had a small 
number of patients. Furthermore, the heterogeneity in the 
methodology and the primary outcomes between studies 
limited the gathering of some clinical parameters evaluated. 
No meta-analysis was possible due to the heterogeneity and 
the impossibility of extracting the necessary data.
Conclusion
In conclusion, this is the most comprehensive systematic 
review to date to show that the NLR is higher in stable COPD 
patients than healthy controls, and that the NLR is also higher 
in exacerbated compared with stable COPD patients. The 
NLR is a good marker for detecting acute exacerbation in 
COPD patients. This systematic review proposes a cut-off 
value of 3.34, which achieves an acceptable degree of accu-
racy. There was no evidence of a relationship between NLR 
and GOLD airflow obstruction classification. However, we 
found that there was a significant correlation between the 
NLR and clinical/functional parameters (FEV
1
, mMRC, 
and BODE index) in COPD patients, which suggests that a 
high NLR could be associated with a worsening of dyspnea, 
clinical performance, and degree of bronchial obstruction. 
Besides, we found that the NLR may provide an added value 
to predict the risk of in-hospital and late mortality in COPD 
patients. Further prospective studies to address confounders 
with larger sample sizes and including different disease stages 
are needed to better identify the clinical value of the NLR.
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